Reference Interval:
| Test Number
| Components
| Reference Interval
| | | Alpha Fetoprotein Total
| 0-15 ng/mL
| | | Alpha Fetoprotein L3 Percent
| Less than 10.0%
|
|
| Interpretive Data: |
The Wako LiBASys method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The Wako AFP-L3% assay is intended as a risk assessment test for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated AFP-L3% values have been shown to be associated with a seven-fold increase in the risk of developing hepatocellular carcinoma within the next 21 months. Patients with elevated serum AFP-L3% should be more intensely evaluated for evidence of hepatocellular carcinoma. The result is not interpretable as a tumor marker in pregnant females.
|
| CPT Code(s): |
82107
|
Cross References: |
AFP (Liver Cancer), AFP-L3%, Alpha Fetoprotein (Liver Cancer), Hepatocellular Carcinoma AFP (Total and L3%) |